Herpes Zoster Vaccination Linked to Lower Risk for MACE, Dementia, Death
Herpes zoster vaccination is associated with lower risks for heart disease, dementia, and mortality among adults aged 50 years and older.
A study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek) found that vaccination against herpes zoster (HZ) reduces the risk of major adverse cardiovascular events (MACE), dementia, and all-cause mortality among older adults with HZ.
Researchers Ali Dehghani, D.O., and George Yendewa, M.D., M.P.H., from Case Western Reserve University School of Medicine in Cleveland, conducted a retrospective matched cohort study to examine the effects of prior zoster vaccination.
- Adults aged 50 years and older with a first-time HZ diagnosis were stratified according to prior vaccination status (vaccinated or unvaccinated).
No direct quote available in the text.
Author's summary: Herpes zoster vaccination lowers risks for heart disease, dementia, and mortality in adults over 50.